P966 Prophylaxis for Pneumocystis pneumonia in non-HIV immunocompromised patients: systematic review and meta-analysis

Abstract Objective Impaired health conditions and related lack of adequate host healing are among the most important conditions that account for dental implant failure. Today clinicians face an increasing number of immunocompromised patients requesting implant-based rehabilitation. To provide clinical evidence for prospective decision-making, the aim of this systematic review and meta-analysis was to analyse the influence of immunodeficiency on dental implant survival. Methods The study was conducted according to the PRISMA Statement and the principles of the Cochrane Collaboration. MEDLINE and Web of Science were searched. Results were calculated by the pooled incidence of implant loss. Reported odds ratios (OR) from fully adjusted models were preferred. Distinct risk estimates were synthesised with 95% confidence intervals. Results A total of 62 publications including 1751 endosseous implants placed in immunocompromised patients were included. For the follow-up of 24 months and longer, the mean survival rate of implants in patients with HIV was 93.1%, chemotherapy was 98.8%, autoimmune disease was 88.75%, after organ transplantation was 100%. Crohn’s disease showed a significant effect on early implant failure and resulted in increased, however not significant, implant loss. Conclusion No significant effect of immunocompromised conditions on implant survival was detectable. Implant-based therapy in immunocompromised patients should not aggravate the general morbidity and must not interfere in life-saving therapies. A careful risk stratification prior implant therapy is fundamental. To further decipher the role of immunosuppression on dental implantology, more data from controlled and randomised studies are needed.

Download Full-text

Cytomegalovirus infection and graft rejection as risk factors for pneumocystis pneumonia in solid organ transplant recipients: A systematic review and meta-analysis

Clinical Transplantation ◽

10.1111/ctr.13339 ◽

2018 ◽

Vol 32 (8) ◽

pp. e13339 ◽

Cited By ~ 10

Author(s):

Seyed M. Hosseini-Moghaddam ◽

Rohin Jayaram Krishnan ◽

Hui Guo ◽

Deepali Kumar

Keyword(s):

Risk Factors ◽

Systematic Review ◽

Cytomegalovirus Infection ◽

Meta Analysis ◽

Organ Transplant ◽

Pneumocystis Pneumonia ◽

Solid Organ Transplant ◽

Solid Organ ◽

Transplant Recipients ◽

Solid Organ Transplant Recipients

Download Full-text

Toxoplasmosis in immunocompromised patients in Iran: a systematic review and meta-analysis

The Journal of Infection in Developing Countries ◽

10.3855/jidc.4796 ◽

2014 ◽

Vol 8 (12) ◽

pp. 1503-1510 ◽

Cited By ~ 55

Author(s):

Ehsan Ahmadpour ◽

Ahmad Daryani ◽

Mahdi Sharif ◽

Shahabeddin Sarvi ◽

Mohsen Aarabi ◽

...

Keyword(s):

Systematic Review ◽

Confidence Interval ◽

Meta Analysis ◽

Scientific Information ◽

Control Measures ◽

Significant Heterogeneity ◽

Seroprevalence Rate ◽

Immunocompromised Patients ◽

Toxoplasma Infection ◽

Hiv Aids

Although toxoplasmosis in immunocompetent individuals is generally asymptomatic, in immunocompromised patients (HIV/AIDS, cancer, and transplant patients), it can lead to serious pathological effects. This study included a systematic review and meta-analysis to comprehensively assess the seroprevalence rate of Toxoplasma infection in immunocompromised patients in Iran. Electronic English and Persian databases (PubMed, Google Scholar, ScienceDirect, Scopus, Magiran, Scientific Information Database [SID], IranMedex, and IranDoc), parasitology congresses, and projects and theses of Iranian medical universities, were systematically searched from 1997 to 2013 (published or unpublished data). In this paper, several studies that used serological methods for diagnosis of toxoplasmosis were selected. Analysis of seroprevalence estimates was pooled using a random-effects meta-analysis. Twenty-two studies, comprising 2,805 individuals, were included in the meta-analysis. Overall seroprevalence rate of Toxoplasma infection in Iranian immunocompromised patients was 50.01% (95% confidence interval, 43.85 to 56.17); however, there was significant heterogeneity among study groups. The results showed that seroprevalence rate of toxoplasmosis among transplant recipients, HIV/AIDS, and cancer patients in Iran was 55.1%, 50.05%, and 45.06%, respectively. In addition, IgM seroprevalence rate was estimated to be 4.85% (95% confidence interval, 2.22 to 8.41). This systematic review and meta-analysis identified a high seroprevalence rate of Toxoplasma infection among immunocompromised patients (50%).Consideration of management , design and provision of appropriate control measures of toxoplasmosis is highly recommended.

Download Full-text